d1,s3,s3-understanding endogenous nitrosation -vs- impact of nitrosamine impurities in drug products
Published 2 years ago • 171 plays • Length 4:56
Download video MP4
Download video MP3
Similar videos
-
10:38
d1,s4a,s3-exploration of forward-looking ideas for inhibiting nitrosamine formation in drug products
-
6:05
d1,s3,s2-remediation of complex nitrosamines
-
13:01
d1,s4a,s5-analytical methods for nitrosamines in pharmaceuticals: progress, pitfalls and prospects
-
10:49
d1,s4b,s1-characterization of excipients in complex dosage forms – fda research & goals
-
14:26
d1,s4a,s4-data gaps & evolving areas in controlling nitrosamine formation: drug products & apis
-
6:00
4. the basic udi di (gmn)
-
38:54
analytical solutions for nitrosamines in response to usp
-
35:40
ipca laboratories ratlam 483 observation june 2023 | learning from observations | api facility
-
11:25
d1,s4a,s6-safety & risk assessment of excipient contributions to nitrosamine formation
-
4:53
d1,s3,s1 -need biorelevant/biopredictive ivr methods for lai, inhalation, other complex generics
-
43:55
nitrosamines analysis - better understanding the risk
-
18:11
nitrosamine impurities; what’s the impact on imps
-
5:00
d1,s3,s4-transitioning to green propellants and the potential impact on generic drugs
-
7:47
comprehensive nitrosamines workflow | shimadzu
-
15:59
overview of current science-based regulatory standards (21of39) complex generics 2018
-
1:22:14
overview of the guidance for industry: control of nitrosamine impurities in human drugs
-
44:52
nitrosamine impurities-aug 2023 ndsris limit usfda guidance | control of nitrosamine guidance feb-21
-
23:53
nitrosamines: where are we now?
-
7:19
nitrosamine impurities || usfda guideline || part-1
-
28:15
nitrosamines - is the worst over? presentation by dr. andrew teasdale
-
1:59
type 1 diabetes research | umass medical school
-
1:44
branded or generics?
Clip.africa.com - Privacy-policy